News and Announcements
Why Is It Attractive To Invest In Australia’s Startups
- Published December 20, 2022 2:06AM UTC
- Publisher Leila Oliveira
- Categories Capital Raising Tips
There has never been a more exciting time to be an Australian startup founder,
investor, or ecosystem participant.
If you don’t believe it, let me show you some data:
1️⃣ Australian startups received more than $10 billion in funding in 2021 -3x more than 2020
2️⃣There were more $100M+ rounds in 2021 than in the prior three years combined, and more $250M+ rounds than in the entire history of the Australian ecosystem.
3️⃣ 682 deals were announced – a 66% increase from 2020
There are more world-class Australian startups being launched, more local investors with more capital to deploy than ever, and more international investors hunting for
Australian deals.
Exciting times ahead!
[tomorrow at 8:00AM Sydney time, I’ll post a breakdown of the top 5 sectors that raised 50% of the total raised in 2021]
via: The state of Australian Startup Funding 2021 report
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
